Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
NCT05303285Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Tongji Hospital. Started Jun 2024; status: recruiting.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05303285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303285.